Legend Biotech (NASDAQ:LEGN) is one of the 17 biotechnology stocks with more than 50% upside. On January 20, Leonid Timashev ...
Jaime Suarez-Londono, MD: Transplant for myeloma is very easy to give. On day 12 they engraft and they go home. Adverse events are not that [severe], and they get this progression-free survival [PFS] ...
The proposed recommendations are intended to safely expedite approvals of promising therapies for multiple myeloma, but one expert is skeptical about the likelihood of industry compliance.
FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.
In the article that accompanies this editorial, de Tute et al 10 show that minimal residual disease (MRD) negativity 3 months after high-dose melphalan chemotherapy followed by autologous stem-cell ...
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat(R) KMT2A + MRD Assay and Software to its industry-leading ...
Minimal residual disease, or MRD, testing may have the potential to offer peace of mind to survivors of breast cancer, as a ...
TORONTO -- Achieving minimal residual disease (MRD) negativity was associated with favorable safety outcomes and no effect on health-related quality of life among patients with newly diagnosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results